Presentation is loading. Please wait.

Presentation is loading. Please wait.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Published byYanti Hardja Modified over 5 years ago

Similar presentations

Presentation on theme: "Expression of CD36 and psap in a TMA of human ovarian cancer patients"— Presentation transcript:

1 Fig. 6. Expression of CD36 and psap in a TMA of human ovarian cancer patients.
Expression of CD36 and psap in a TMA of human ovarian cancer patients. (A) Expression of CD36 in a tumor TMA compiled from normal tissue, primary human ovarian tumors, human ovarian cancer visceral metastases (metastases), and human ovarian cancer lymph node metastases (LN mets) (black scale bars, 200 μm; yellow scale bars, 50 μm). (B) Plot of CD36 SIs for normal human ovarian and endometrial tissue, primary human ovarian tumors, human ovarian cancer metastases, and human ovarian cancer lymph node metastases (P values were determined by Wilcoxon-Mann-Whitney analysis) (mean ± SEM). (C) Expression of psap in a tumor TMA compiled from normal tissue, primary human ovarian tumors, human ovarian cancer visceral metastases (metastases), and human ovarian cancer lymph node metastases (LN mets) (scale bars, 50 μm). (D) Plot of psap SIs for normal human ovarian and endometrial tissue, primary human ovarian tumors, human ovarian cancer metastases, and human ovarian cancer lymph node metastases (P values were determined by Wilcoxon-Mann-Whitney analysis) (mean ± SEM). Suming Wang et al., Sci Transl Med 2016;8:329ra34 Published by AAAS

Download ppt "Expression of CD36 and psap in a TMA of human ovarian cancer patients"

Similar presentations

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.
Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
LTB4 production is elevated in preclinical and clinical lymphedema

LTB4 production is elevated in preclinical and clinical lymphedema
Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.
Fig. 2 LYM attractor metagene.

Fig. 2 LYM attractor metagene.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 3 TLR8 signaling induces CXCL4 and IFN-α secretion by SSc PDCs.

Fig. 3 TLR8 signaling induces CXCL4 and IFN-α secretion by SSc PDCs.
Intravenous delivery of reovirus to primary and secondary brain tumors

Intravenous delivery of reovirus to primary and secondary brain tumors
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.
Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Similar presentations

Ads by Google